BerGenBio Cocktail Event at ASCO

Chicago, IL, June 2, 2018
BerGenBio is delighted to invite you to meet the company's management team & clinical investigators

for
COCKTAILS & CANAPES
and short presentations on 

selective AXL inhibitor bemcentinib (BGB324), 
in phase II clinical development as a potential cornerstone of cancer combination therapy.

- BerGenBio reception at ASCO -
The School of the Art Institute Ballroom
112 S Michigan Ave, Chicago, IL 60603

Saturday June 2nd 2018: 6-8 p.m. (Central)

Materials

General Agenda

The event will include an overview of BerGenBio's business and Phase II clinical trial updates for our lead product bemcentinib, a potent first-in-class, highly selective, and orally bioavailable small molecule AXL kinase inhibitor as potential cornerstone therapy for cancer. Trials include key combination therapies using immune checkpoint inhibitors (KEYTRUDA), targeted therapies and chemotherapy for NSCLC, AML,

Dr Jim Lorens
BerGenBio, CMO

image_7zfo53.png

Scientific co-founder,
Rigel Inc. and
BerGenBio, AXL biology
driving aggressive
disease
(Read here)

Dr Corey Hogaboam
Cedars-Sinai Medical

image_wk69fm.png

KOL, AXL’s role in
idiopathic pulmonary
fibrosis (IPF)
(Read here)

Dr David Gerber
UT Southwestern

image_qqgfkh.png

Sponsor investigator,
combination trial of
bemcentinib with
docetaxel in NSCLC
(Read here)

     

Dr Sonja Loges
Univ Medical Ctr Hamburg-Eppendorf

image_ujwdpx.png

PI, bemcentinib
monotherapy and
combination in AML/MDS
(Read here)

Dr Oddbjørn Straume
University of Bergen

image_ch67gw.png

Sponsor investigator,
combination trial of
bemcentinib with
KEYTRUDA or BRAF
inhibitors in melanoma
(Read here)

Dr Matthew Krebs
The Christie

image_aadagt.png

PI, combination trial of
bemcentinib and
KEYTRUDA in NSCLC
(Read here)

Please feel free to forward this invitation to interested colleagues.
Looking forward to meeting you in Chicago,
Richard Godfrey, CEO

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

BerGenBio [BGBIO:OS] NKr1,871 MM MCap
Ber­Gen­Bio ASA is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing a pipe­line of first-in-class AXL ki­nase in­hibi­tors as a po­ten­tial corn­er­s­tone of com­bi­na­tion can­cer ther­a­py. The... [more in­for­ma­tion]

Event Contact

Thomas Hoffmann
Solebury Trout

Location of the Event and Other Places